OCGNHealthcare · BiotechnologyThe 6 Wall Street analysts covering Ocugen, Inc. hold a median 12-month price target of $11 — +974.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +974.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.50 |
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | $12 → $11 |
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Mar 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 5 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2025 | Chardan Capital | Maintains | Buy | — |
| 12 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Ocugen, Inc. returned −45.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 4% of US stocks
Cheaper than 98% of US stocks
Cheaper than 79% of US stocks
Higher than 48% of US stocks
Higher than 46% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ocugen, Inc. has a market value of $352.7M and an enterprise value of $340.6M.
Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter grew 8.4% year on year.
Net income over the same four quarters: −$81.8M, a −1786.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.25.
Free cash flow in the twelve months to 30 June 2026: −$61.0M.
Trailing P/E: −4.5×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ocugen, Inc. employs 116 people — $39K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PRNewsWire invited Ocugen shareholders to contact a firm to discuss their rights and options at no cost or obligation. The firm said it would handle matters on a contingent-fee basis, with no out-of-pocket payment for its legal fees or expenses.
Why it matters — The item raises a shareholder-rights issue involving Ocugen, which may be relevant to investors following the company.
Hemostemix announced full approval from The Bahamas’ LARTA Board, including ethics approval, for a commercial Phase 1 study of VesCell™ to treat angina, vascular dementia and pain.
Why it matters — The announcement concerns Hemostemix and does not describe a development or update involving Ocugen.
Ocugen appointed Jolanda Crombach, MSc PharmD, as General Manager of its newly established European affiliate, headquartered in Amsterdam. Crombach has more than 20 years of pharmaceutical industry experience.
Why it matters — The appointment places an experienced pharmaceutical executive in charge of Ocugen’s European affiliate.
Ocugen, Inc. announced that it will present on its modifier gene therapy platform at upcoming scientific conferences. The presentations will highlight the company's gene therapies aimed at blindness diseases.
Why it matters — OCGN watchers would care because these conference presentations offer an opportunity to see the company's modifier gene therapy platform showcased to the scientific community.
Ocugen announced that members of its executive leadership team will present at two upcoming investor and industry conferences in October. The announcement was made by the company on September 29, 2026.
Why it matters — Conference presentations offer OCGN watchers visibility into how the company plans to communicate its gene therapy pipeline and business strategy to investors and industry audiences.
The 6 Wall Street analysts covering Ocugen, Inc. have a median 12-month price target of $11, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 21 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Ocugen, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +974.3% from the last close, and Ticker Nerd's factor model ranks Ocugen, Inc. 21 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.
Ocugen, Inc. returned -45.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions.
The most recent item we track (PRNewsWire, 8 Oct 2026): "Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". PRNewsWire invited Ocugen shareholders to contact a firm to discuss their rights and options at no cost or obligation. The firm said it would handle matters on a contingent-fee basis, with no out-of-pocket payment for its legal fees or expenses.
Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address inherited retinal diseases and multifactorial eye disorders, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. The company also works on cell therapy and vaccine-related research through selective programs and collaborations, reflecting a broader focus on unmet medical needs in ophthalmology and infectious disease. Ocugen’s pipeline includes product candidates under clinical development rather than marketed therapies, so its role in the market is primarily tied to research, development, and partnership-driven innovation. Headquartered in Malvern, Pennsylvania, Ocugen Inc. operates as a biotechnology company concentrated on advancing treatments for patients with limited current options.
CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com
